AstraZeneca-Amgen Tezspire Gets USFDA Nod for Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca-Amgen Tezspire gets USFDA nod for chronic rhinosinusitis with nasal polyps

AstraZeneca and Amgen's Tezspire (tezepelumab) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with inadequately controlled...

FDA approves tezepelumab for CRSwNP in patients 12 years and up

Tezepelumab received FDA approval for CRSwNP in patients 12 years and older, supported by strong phase 3 data.

~320M affected: AstraZeneca's TEZSPIRE approved in US for CRSwNP in patients 12+, first TSLP biologic

AstraZeneca/Amgen TEZSPIRE approved by FDA as add-on maintenance for CRSwNP in patients ≥12. WAYPOINT Phase III showed reduced polyp severity, near-elimination of surgery and lower steroid use (52-week).